1-16 of 16
programmed cell death 1 ligand 1
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial

Clinical Trials & Observations
Alex F. Herrera, Catherine Burton, John Radford, Fiona Miall, William Townsend, Armando Santoro, Pier Luigi Zinzani, David Lewis, Camilla Fowst, Satjit Brar, Bo Huang, Aron Thall, Graham P. Collins
Journal: Blood Advances
Blood Adv (2021) 5 (17): 3387–3396.
https://doi.org/10.1182/bloodadvances.2021004511
Published: 2021
Includes: Supplemental data
Journal Articles

Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation

Zachary Davis, Martin Felices, Todd Lenvik, Sujan Badal, Joshua T. Walker, Peter Hinderlie, James L. Riley, Daniel A. Vallera, Bruce R. Blazar, Jeffrey S. Miller
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1069–1080.
https://doi.org/10.1182/bloodadvances.2019001110
Published: 2021
Includes: Supplemental data
Journal Articles

Pembrolizumab in mycosis fungoides with PD-L1 structural variants

Clinical Trials & Observations
Sara Beygi, Sebastian Fernandez-Pol, George Duran, Erica B. Wang, Henning Stehr, James L. Zehnder, Nirasha Ramchurren, Steven P. Fling, Martin A. Cheever, Wen-Kai Weng, Youn H. Kim, Michael S. Khodadoust
Journal: Blood Advances
Blood Adv (2021) 5 (3): 771–774.
https://doi.org/10.1182/bloodadvances.2020002371
Published: 2021
Journal Articles

Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas

Alexander Neuwelt, Taha Al-Juhaishi, Eduardo Davila, Bradley Haverkos
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4256–4266.
https://doi.org/10.1182/bloodadvances.2020001966
Published: 2020
Journal Articles

LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma

Colm Keane, Soi C. Law, Clare Gould, Simone Birch, Muhammed B. Sabdia, Lilia Merida de Long, Gayathri Thillaiyampalam, Emad Abro, Joshua W. Tobin, Xiaohong Tan, Zijun Y. Xu-Monette, Ken H. Young, Grace Gifford, Sara Gabreilli, William S. Stevenson, Anthony Gill, Dipti Talaulikar, Sanjiv Jain, Annette Hernandez, Sarah-Jane Halliday, Robert Bird, Donna Cross, Mark Hertzberg, Maher K. Gandhi
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1367–1377.
https://doi.org/10.1182/bloodadvances.2019001390
Published: 2020
Includes: Supplemental data
Journal Articles

Acute myeloid leukemia–induced T-cell suppression can be reversed by inhibition of the MAPK pathway

Kaycee B. Moshofsky, Hyun J. Cho, Guanming Wu, Kyle A. Romine, Matthew T. Newman, Yoko Kosaka, Shannon K. McWeeney, Evan F. Lind
Journal: Blood Advances
Blood Adv (2019) 3 (20): 3038–3051.
https://doi.org/10.1182/bloodadvances.2019000574
Published: 2019
Journal Articles

Mixed chimerism established by hematopoietic stem cell transplantation is maintained by host and donor T regulatory cells

Clinical Trials & Observations
Francesca A. M. Kinsella, Jianmin Zuo, Charlotte F. Inman, Hayden Pearce, Luke Maggs, Suzy E. Eldershaw, Y. L. Tracey Chan, Jane Nunnick, Sandeep Nagra, Mike Griffiths, Charles Craddock, Ram Malladi, Paul Moss
Journal: Blood Advances
Blood Adv (2019) 3 (5): 734–743.
https://doi.org/10.1182/bloodadvances.2018025502
Published: 2019
Includes: Supplemental data
Journal Articles

PD-L1 and tumor-associated macrophages in de novo DLBCL

Clinical Trials & Observations
Ronald McCord, Christopher R. Bolen, Hartmut Koeppen, Edward E. Kadel, III, Mikkel Z. Oestergaard, Tina Nielsen, Laurie H. Sehn, Jeffrey M. Venstrom
Journal: Blood Advances
Blood Adv (2019) 3 (4): 531–540.
https://doi.org/10.1182/bloodadvances.2018020602
Published: 2019
Includes: Supplemental data
Journal Articles

MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas

Naema Nayyar, Michael D. White, Corey M. Gill, Matthew Lastrapes, Mia Bertalan, Alexander Kaplan, Megan R. D’Andrea, Ivanna Bihun, Andrew Kaneb, Jorg Dietrich, Judith A. Ferry, Maria Martinez-Lage, Anita Giobbie-Hurder, Darrell R. Borger, Fausto J. Rodriguez, Matthew P. Frosch, Emily Batchelor, Kaitlin Hoang, Benjamin Kuter, Sarah Fortin, Matthias Holdhoff, Daniel P. Cahill, Scott Carter, Priscilla K. Brastianos, Tracy T. Batchelor
Journal: Blood Advances
Blood Adv (2019) 3 (3): 375–383.
https://doi.org/10.1182/bloodadvances.2018027672
Published: 2019
Journal Articles

Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia

Shahrzad Jalali, Tammy Price-Troska, Jonas Paludo, Jose Villasboas, Hyo-Jin Kim, Zhi-Zhang Yang, Anne J. Novak, Stephen M. Ansell
Journal: Blood Advances
Blood Adv (2018) 2 (15): 1985–1997.
https://doi.org/10.1182/bloodadvances.2018021113
Published: 2018
Journal Articles

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy

Sara Mastaglio, Eric Wong, Travis Perera, Jane Ripley, Piers Blombery, Mark J. Smyth, Rachel Koldej, David Ritchie
Journal: Blood Advances
Blood Adv (2018) 2 (4): 335–346.
https://doi.org/10.1182/bloodadvances.2017015230
Published: 2018
Includes: Supplemental data
Journal Articles

Variability of PD-L1 expression in mastocytosis

Clinical Trials & Observations
Ellen W. Hatch, Mary Beth Geeze, Cheyenne Martin, Mohamed E. Salama, Karin Hartmann, Gregor Eisenwort, Katharina Blatt, Peter Valent, Jason Gotlib, Ji-Hyun Lee, Lu Chen, Heather H. Ward, Diane S. Lidke, Tracy I. George
Journal: Blood Advances
Blood Adv (2018) 2 (3): 189–199.
https://doi.org/10.1182/bloodadvances.2017011551
Published: 2018
Includes: Supplemental data
Journal Articles

Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma

Reid W. Merryman, Philippe Armand, Kyle T. Wright, Scott J. Rodig
Journal: Blood Advances
Blood Adv (2017) 1 (26): 2643–2654.
https://doi.org/10.1182/bloodadvances.2017012534
Published: 2017
Journal Articles

High proportions of PD-1 + and PD-L1 + leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome

Clinical Trials & Observations
Peter Hollander, Peter Kamper, Karin Ekstrom Smedby, Gunilla Enblad, Maja Ludvigsen, Julie Mortensen, Rose-Marie Amini, Stephen Hamilton-Dutoit, Francesco d’Amore, Daniel Molin, Ingrid Glimelius
Journal: Blood Advances
Blood Adv (2017) 1 (18): 1427–1439.
https://doi.org/10.1182/bloodadvances.2017006346
Published: 2017
Includes: Supplemental data
Journal Articles

Th17 immune microenvironment in Epstein-Barr virus–negative Hodgkin lymphoma: implications for immunotherapy

Clinical Trials & Observations
Amy S. Duffield, Maria Libera Ascierto, Robert A. Anders, Janis M. Taube, Alan K. Meeker, Shuming Chen, Tracee L. McMiller, Neil A. Phillips, Haiying Xu, Aleksandra Ogurtsova, Alan E. Berger, Drew M. Pardoll, Suzanne L. Topalian, Richard F. Ambinder
Journal: Blood Advances
Blood Adv (2017) 1 (17): 1324–1334.
https://doi.org/10.1182/bloodadvances.2017007260
Published: 2017
Includes: Supplemental data
Journal Articles

Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities

Global Advances
Elizabeth A. Morgan, M. Patrick Sweeney, Tamiwe Tomoka, Nadja Kopp, Daniel Gusenleitner, Robert A. Redd, Christopher D. Carey, Leo Masamba, Steve Kamiza, Geraldine S. Pinkus, Donna S. Neuberg, Scott J. Rodig, Danny A. Milner, Jr, David M. Weinstock
Journal: Blood Advances
Blood Adv (2016) 1 (1): 84–92.
https://doi.org/10.1182/bloodadvances.2016000026
Published: 2016
Includes: Supplemental data